Purpose: Oxcarbazepine is known as an effective first-line monotherapy for pediatric focal epilepsy. Lamotrigine has also been reported to have similar efficacy to and better tolerability than carbamazepine. Therefore, the effectiveness of oxcarbazepine and lamotrigine monotherapies was compared in patients with pediatric focal epilepsy. Method: A total of 116 patients in pediatric patients with partial epilepsy received lamotrigine (n = 43) or oxcarbazepine (n = 73) monotherapy. The clinical characteristics, seizure outcomes, reasons for drug discontinuation, retention rate and adverse effects were evaluated for each drug. Results: Oxcarbazepine was more commonly used than lamotrigine (69/73 vs. 23/43) as initial monotherapy. Lamotrigine showed better efficacy than oxcarbazepine in terms of the seizure outcome more than 12 months (P < 0.05). Oxcarbazepine and lamotrigine showed similar tolerability in terms of the retention rate, drug discontinuation and adverse effects. The rates of successful discontinuation were similar for patients receiving these drug as initial monotherapy (P > 0.05). The seizure outcome was much better for lamotrigine than for oxcarbazepine in patients with normal MRI findings and normal development (P = 0.001, P = 0.01). The retention rate was high in patients with MRI abnormalities or developmental delay in the lamotrigine group. The choice of lamotrigine was the only independent variable that predicted a seizure-free state, even after correcting for clinical variables (OR = 4.80, P = 0.013). Conclusions: Lamotrigine was superior to oxcarbazepine monotherapy because of its greater effectiveness in treating pediatric focal epilepsy. Lamotrigine can be selected as a first-line monotherapy in patients with or without abnormal MRI findings or delayed development.
Introduction
Evidence-based medicine is an approach used for characterizing antiepileptic drugs for optimized decision-making since both traditional and new antiepileptic drugs have been introduced to the field of focal epilepsy. Evidence-based medicine guides treatment in certain specific populations, but neurologists should not overlook clinicians' personal experience and patient-related factors, including age, comorbidity, adverse effects and economic state, when deciding how to treat patients [1] .
In pediatric focal epilepsy, the selection of an antiepileptic drug is supported by limited evidence compared to adult epilepsy. The guidance for evidence-based medicine in adult epilepsy studies may frequently be less helpful for the treatment of pediatric focal epilepsy. In adult focal epilepsy, carbamazepine has been demonstrated as the best initial treatment option due to its efficacy and safety profile and new antiepileptic drugs especially lamotrigine (LTG) with better tolerability have also been shown to be comparable to carbamazepine [1] [2] [3] [4] [5] . In pediatric focal epilepsy, only oxcarbazepine (OXC) is known to be an effective first-line monotherapy with class I evidence for efficacy [3, 6] . ILAE evidence review reported that OXC was established as the only adequate comparator as initial monotherapy through meta-analysis for newly diagnosed or untreated partial epilepsy in children although OXC was not compared with carbamazepine in children [3] . This study reports a comparison of LTG and OXC regarding their efficacy and tolerability in pediatric focal epilepsy.
Patients and methods
Patients with either newly diagnosed partial epilepsy or a relapse following the withdrawal or failure of a previous monotherapy other than LTG or OXC were retrospectively evaluated from March 2010 to December 2016. A total of 116 patients younger than 18 years who received OXC (n = 73) or LTG (n = 43) as a monotherapy were enrolled from pediatric neurology databases (Fig. 1) . Patients receiving antiepileptic polytherapy or other medical treatments were excluded. Four patients in the OXC group and 20 patients in the LTG group had received previous antiepileptic medication. Five patients in the LTG group had received two antiepileptic drugs previously as monotherapy. The previous used drugs were valproic acid, levetiracetam, topiramate and zonisamide. The patients had partial epilepsy, including simple partial, complex partial, and secondary generalized tonic-clonic seizures. This study was approved by the institutional review board of Inje University Haeundae Paik Hospital, and the data were analyzed without information regarding patient identities.
The effectiveness of each drug was evaluated based on its efficacy and tolerability. To compare the effectiveness of OXC and LTG, clinical characteristics, including age, sex, age of seizure onset, seizure type, development, magnetic resonance imaging (MRI) abnormalities and duration of follow-up, were evaluated using a standard data collection form. The dosage, line of therapy, adverse effects, seizure outcome, reason for discontinuation and retention rate were also evaluated for each drug. The efficacy of each drug was determined by a seizure-free outcome, successful discontinuation, and the seizure reduction rate. Seizure outcome was evaluated by the degree of seizure reduction at the last visit based on the frequency of seizures before starting the medication and after 12 months, when the drug was administered as a maintenance dose. A seizure-free outcome was defined by no seizures for more than 12 months after receiving the medication. If the seizurefree period was longer than 12 months but patients experienced seizure recurrence during follow-up after the maintenance was achieved, the patients were not regarded as a seizure-free. The maintenance dose for each drug ranged from 1 to 9 mg/kg (mean 4.9 mg/kg) in the LTG group and from 15 to 40 mg/kg (mean 21.6 mg/kg) in the OXC group. The titration time to reach the maintenance dose was more than 2 months for LTG and 2 weeks for OXC. Except for three patients, all patients were included in the evaluation of seizure outcome because they had a follow-up duration of more than 12 months while receiving the maintenance drug dose, although some patients were lost to followup or discontinued the drug due to ineffectiveness. Three patients receiving LTG monotherapy were excluded from the evaluation of seizure outcome because their follow-up duration was less than 12 months while receiving the maintenance drug dose. Two patients exhibited a skin rash after starting LTG and discontinued use immediately. While using the medication, the frequency of seizures was unchanged. One patient who had bad breath and a skin rash discontinued LTG use but exhibited a seizure-free outcome after starting LTG at a dose of 3 mg/ kg. Their dose of LTG ranged from 1 to 3 mg/kg. Tolerability was assessed by the retention rate and discontinuation due to ineffectiveness or intolerable adverse effects. Drug retention was evaluated by maintenance of the medication as a monotherapy for at least two years. The retention rate was evaluated in 40 patients treated with LTG and in 62 patients treated with OXC monotherapy with a follow-up duration of more than two years.
The results of patients using OXC and LTG were statistically compared using the chi-square test, Fisher's exact test and the MannWhitney U test; these assessments were conducted using SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, New York). A value of P < 0.05 was regarded as indicative of statistical significance.
Results
The mean patient age of the LTG group was approximately two years older than that of the OXC group, but the age distributions were not significantly different. The age of seizure onset, male-to-female ratio, and other clinical manifestations were also not different (Table 1) . Six patients had benign rolandic epilepsy including two patients in the LTG group and four patients in the OXC group. Two patients had benign occipital epilepsy of childhood including one patient each in the LTG and OXC groups. Twenty-five patients exhibited MRI abnormalities, and 17 patients showed developmental delays. The ten patients (23.3%) were treated with LTG monotherapy, including two with focal cortical dysplasia, two with heterotopia, and one each with venous angioma, subependymoma, encephalomalacia, Dandy-Walker syndrome, cerebellar atrophy and hippocampal sclerosis. The fifteen patients (20.5%) treated with OXC monotherapy included six with encephalomalacia, three with heterotopia, two with focal cortical dysplasia, and one each with arachnoid cysts, cerebellar hypoplasia, venous angioma and inflammation. OXC (94.5%) was more commonly used than LTG (53.5%) as initial monotherapy (Fig. 1) . More seizure- free outcomes were observed in the LTG group than in the OXC group (P = 0.005), and the degree of seizure reduction differed between the two groups (P = 0.04, Table 2 ). Of all patients receiving monotherapy, 65.5% had a seizure-free outcome, and 44.2% had successful discontinuation of the drug. The seizure-free outcome of patients receiving these drugs as initial monotherapy (LTG; 18/22, OXC; 40/69, P = 0.047), as well as that of patients receiving these drugs as secondor third-line monotherapy (P = 0.044, P = 0.007, respectively) was superior in the LTG group, although the rates of successful discontinuation were similar for patients receiving these drugs as initial monotherapy (LTG; 11/22, OXC; 30/69, P > 0.05). The seizure outcome was much better for LTG than OXC in patients with normal MRI scans and normal development (P = 0.001, P = 0.01). Among patients with MRI abnormalities, four patients using LTG (n = 9) and eight patients using OXC monotherapy (n = 15) showed seizure-free outcomes. One patient using LTG was not included in the evaluation of seizure outcome due to discontinuation of LTG. No differences in seizure outcome according to MRI abnormalities were observed between the two groups (P = 0.68). Delayed development was observed in six patients in the LTG group and 11 patients in the OXC group. No differences were found in seizure-free outcome between the groups among patients with delayed development (P = 0.28). Among the clinical factors affecting seizure-free outcome, LTG monotherapy was the only independent factor that could predict a seizure-free state (OR = 4.80, P = 0.013) in the multiple logistic regression analysis, even after correcting for clinical variables ( Table 3 ).
The two-year retention rate was evaluated in 102 patients (Table 2) . Three patients using LTG and 11 patients using OXC had a follow-up duration of more than one but less than 2 years and were excluded from the drug retention calculations. The retention rate of the LTG group was 82.5% and that of the OXC group was 80.6% (P = 0.81). The retention rate was higher among patients with MRI abnormalities (77.8% vs. 60.0%) and with delayed development in the LTG group than in the OXC group (83.3% vs. 36.4%). The occurrence of adverse events and the follow-up duration were influential clinical factors that affected the 2-year retention rate (OR = 0.01, P = 0.003; OR = 2.35, P = 0.002, respectively). The main reasons for drug discontinuation were ineffectiveness in the OXC group and adverse effects in the LTG group. OXC was discontinued by 17 patients due to ineffectiveness, while LTG was discontinued by one patient due to ineffectiveness and by three patients due to adverse effects, such as rash and abnormal oral sensations with bad breath (23% vs. 9%, P = 0.06).
Discussion
This study found that LTG monotherapy was superior to OXC monotherapy with regard to remission from seizures for longer than 12 months in pediatric focal epilepsy patients. LTG also showed a low withdrawal rate due to ineffectiveness, with only three patients discontinuing its use during the evaluation of seizure outcomes. In the intention to treat analysis, the overall outcomes for patients starting each antiepileptic drug (n = 116) were seizure-free status in 34 patients, 50% or greater seizure reduction in three patients, and less than 50% seizure reduction in six patients in the LTG group (n = 43) and seizure-free status in 41 patients, 50% or greater seizure reduction in 10 patients, and less than 50% seizure reduction in 22 patients in the OXC group (n = 73). When the efficacies of LTG and OXC were determined, LTG was superior to OXC (P = 0.045). In a meta-analysis, LTG was superior in terms of tolerability, but carbamazepine monotherapy showed a superior trend for seizure control [7] . However, other metaanalyses have reported that the best option for seizure outcome and tolerability was LTG in focal epilepsy [1, 8] . LTG showed better tolerability than carbamazepine in two randomized controlled studies, although the studies were limited by the small sample size of pediatric patients [5, 9] . An ILAE evidence review showed that the effectiveness of levetiracetam, zonisamide, carbamazepine and phenytoin as initial monotherapies in adult focal epilepsy was established in published randomized controlled studies [3] . However, few published class I or II randomized controlled studies have examined pediatric focal epilepsy, which prevents drawing conclusions regarding the efficacy of several antiepileptic drugs. OXC has been established as the only adequate comparable initial monotherapy [3] . In the SANAD randomized controlled trial, LTG did not show an advantage over OXC in terms of time to treatment failure and time to 12-month remission in adults with partial epilepsy [10] . Although this study was observational and not a randomized controlled study, the results showed that LTG monotherapy was significantly more effective than OXC monotherapy, with similar tolerability. Considering the clinical factors of seizure-free outcome, the antiepileptic drug selection for LTG was only an independent factor although the influential factors concerning the 2-year retention rate were the presence of adverse effects and the follow-up duration. This study also found that LTG was superior to OXC in controlling seizures in patients with normal MRI findings or normal development, while the drugs had similar effects in patients with MRI abnormalities or developmental delays. In a study of benign Rolandic epilepsy, levetiracetam monotherapy resulted in non-significant higher seizure-free rate than OXC (90% vs. 72.2%) [11] . This study showed seizure-free outcomes in both LTG and OXC monotherapy for patients with benign rolandic epilepsy. Patients with normal development and normal MRI findings showed a superior response to LTG compared to OXC. LTG demonstrated greater tolerability than OXC in patients with MRI abnormalities or delayed development, although the difference was not significant. LTG can be an effective drug for patients with normal MRI findings and normal development. LTG may also be a good option in terms of tolerability for patients with MRI abnormalities or delayed development.
Conclusions
LTG can be selected as a first-line monotherapy for pediatric focal epilepsy patients with or without MRI abnormalities or delayed development. This study was limited because it was an observational study and therefore had less impact than a randomized controlled study. A randomized controlled study that directly compares the effects of LTG and OXC is needed, although studies have evaluated comparable antiepileptic drugs in pediatric focal epilepsy patients by meta-analysis [8] .
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